Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A
Sign Up to like & getrecommendations! Published in 2022 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2022.2062180
Abstract: Abstract Objective To evaluate real-world annualized bleeding rates (ABRs), dosing frequency, and factor consumption of four recombinant FVIII (rFVIII) products using pooled data from centers in the US, Germany, and Italy. Methods De-identified patient medical… read more here.
Keywords: rviii singlechain; consumption; octocog alfa; bay 8973 ... See more keywords
Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe Hemophilia A in Italy.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2194803
Abstract: Introduction: rVIII-SingleChain, a recombinant factor VIII (rFVIII), has demonstrated safety and efficacy in patients with hemophilia A in clinical trials and real-world evidence. This analysis aimed to estimate the potential budget impact of increasing the… read more here.
Keywords: rviii singlechain; singlechain; analysis; budget impact ... See more keywords
A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2020.20199
Abstract: BACKGROUND Patients with hemophilia A are commonly treated with replacement recombinant factor VIII (rFVIII) products, which can be standard-acting or long-acting. Long-acting products have modifications, offering the potential for reduced dosing frequency while maintaining therapeutic… read more here.
Keywords: fviii products; long acting; rviii singlechain; bay ... See more keywords